{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:06:49Z","timestamp":1768194409286,"version":"3.49.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","geriatriconcology.net","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.jgo.2018.01.008","type":"journal-article","created":{"date-parts":[[2018,2,18]],"date-time":"2018-02-18T04:07:34Z","timestamp":1518926854000},"page":"291-295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["How to treat chronic myeloid leukemia (CML) in older adults"],"prefix":"10.1016","volume":"9","author":[{"given":"Marlise R.","family":"Luskin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jgo.2018.01.008_bb0005","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jgo.2018.01.008_bb0010","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2141.1997.d01-1982.x","article-title":"Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period","volume":"96","author":"Savage","year":"1997","journal-title":"Br J Haematol"},{"issue":"17","key":"10.1016\/j.jgo.2018.01.008_bb0015","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jgo.2018.01.008_bb0020","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood.V84.12.4064.bloodjournal84124064","article-title":"Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group","volume":"84","author":"Hehlmann","year":"1994","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jgo.2018.01.008_bb0025","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7326\/0003-4819-122-4-199502150-00003","article-title":"Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service","volume":"122","author":"Kantarjian","year":"1995","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.jgo.2018.01.008_bb0030","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1046\/j.1365-2141.2000.02229.x","volume":"110","year":"2000","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.jgo.2018.01.008_bb0035","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1056\/NEJM198601233140403","article-title":"Bone marrow transplantation for patients with chronic myeloid leukemia","volume":"314","author":"Goldman","year":"1986","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jgo.2018.01.008_bb0040","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1200\/JCO.1987.5.7.1033","article-title":"Therapy of chronic myelogenous leukemia with allogeneic bone marrow transplantation","volume":"5","author":"McGlave","year":"1987","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2018.01.008_bb0045","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V80.5.1352.1352","article-title":"Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2","volume":"80","author":"Biggs","year":"1992","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.jgo.2018.01.008_bb0050","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jgo.2018.01.008_bb0055","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.jgo.2018.01.008_bb0060","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jgo.2018.01.008_bb0065","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","article-title":"Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008","volume":"29","author":"Bjorkholm","year":"2011","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.jgo.2018.01.008_bb0070","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.jgo.2018.01.008_bb0075","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jgo.2018.01.008_bb0080","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jgo.2018.01.008_bb0085","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jgo.2018.01.008_bb0090","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"364","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jgo.2018.01.008_bb0095","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jgo.2018.01.008_bb0100","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.jgo.2018.01.008_bb0105","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jgo.2018.01.008_bb0110","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.6004\/jnccn.2016.0162","article-title":"Chronic myelogenous leukemia, version 1.2017","volume":"14","author":"Pallera","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"10.1016\/j.jgo.2018.01.008_bb0115","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network","volume":"105","author":"Smith","year":"2011","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.jgo.2018.01.008_bb0120","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/leu.2008.245","article-title":"Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph\/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany","volume":"23","author":"Rohrbacher","year":"2009","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.jgo.2018.01.008_bb0125","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jgo.2018.01.008_bb0130","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood-2012-03-378919","article-title":"How I treat newly diagnosed chronic phase CML","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jgo.2018.01.008_bb0135","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1182\/asheducation-2016.1.164","article-title":"Chronic myeloid leukemia: sequencing of TKI therapies","volume":"2016","author":"Cortes","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"10.1016\/j.jgo.2018.01.008_bb0140","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.jgo.2018.01.008_bb0145","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jgo.2018.01.008_bb0150","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jgo.2018.01.008_bb0155","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.jgo.2018.01.008_bb0160","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.neo.2016.07.005","article-title":"Frontline dasatinib treatment in a \u201creal-life\u201d cohort of patients older than 65\u202fyears with chronic myeloid leukemia","volume":"18","author":"Latagliata","year":"2016","journal-title":"Neoplasia"},{"issue":"8","key":"10.1016\/j.jgo.2018.01.008_bb0165","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"issue":"48","key":"10.1016\/j.jgo.2018.01.008_bb0170","doi-asserted-by":"crossref","first-page":"80083","DOI":"10.18632\/oncotarget.11657","article-title":"Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome","volume":"7","author":"Iurlo","year":"2016","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.jgo.2018.01.008_bb0175","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.clml.2015.09.008","article-title":"Use of real-world claim databases to assess prevalence of comorbid conditions relevant to the treatment of chronic myelogenous leukemia based on National Comprehensive Network treatment guidelines","volume":"15","author":"Jabbour","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.jgo.2018.01.008_bb0180","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.jgo.2018.01.008_bb0185","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jgo.2018.01.008_bb0190","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.jgo.2018.01.008_bb0195","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jgo.2018.01.008_bb0200","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1182\/asheducation.V2017.1.102.00014","article-title":"Treatment-free remission in CML: who, how, and why?","volume":"1","author":"Mahon","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"10.1016\/j.jgo.2018.01.008_bb0210","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.leukres.2011.05.015","article-title":"Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant\/intolerant to imatinib","volume":"35","author":"Latagliata","year":"2011","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.jgo.2018.01.008_bb0215","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s40266-013-0088-6","article-title":"Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study","volume":"30","author":"Latagliata","year":"2013","journal-title":"Drugs Aging"},{"issue":"17","key":"10.1016\/j.jgo.2018.01.008_bb0220","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2018.01.008_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(17)30066-2","article-title":"De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial","volume":"4","author":"Clark","year":"2017","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.jgo.2018.01.008_bb0230","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clml.2017.02.023","article-title":"Elderly patients with chronic myeloid leukemia benefit from a dasatinib dose as low as 20\u202fmg","volume":"17","author":"Itamura","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.jgo.2018.01.008_bb0235","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2018.01.008_bb0240","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.jgo.2018.01.008_bb0245","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jgo.2018.01.008_bb0250","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.3109\/10428194.2014.994205","article-title":"Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment","volume":"56","author":"Gora-Tybor","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.jgo.2018.01.008_bb0255","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.clml.2012.04.005","article-title":"Nilotinib-associated vascular events","volume":"12","author":"Quintas-Cardama","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.jgo.2018.01.008_bb0260","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/ejh.12096","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study","volume":"90","author":"Levato","year":"2013","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.jgo.2018.01.008_bb0265","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.jgo.2018.01.008_bb0270","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/ejh.12367","article-title":"Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome","volume":"94","author":"Mirault","year":"2015","journal-title":"Eur J Haematol"},{"issue":"14","key":"10.1016\/j.jgo.2018.01.008_bb0275","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.jacc.2013.01.004","article-title":"Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF\/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"Rooke","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.jgo.2018.01.008_bb0280","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2013-10-532341","article-title":"Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study","volume":"123","author":"Shah","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jgo.2018.01.008_bb0285","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cncr.24734","article-title":"Dasatinib 100\u202fmg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion","volume":"116","author":"Porkka","year":"2010","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jgo.2018.01.008_bb0290","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hon.2020","article-title":"Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia","volume":"31","author":"Latagliata","year":"2013","journal-title":"Hematol Oncol"},{"issue":"10","key":"10.1016\/j.jgo.2018.01.008_bb0295","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.3324\/haematol.2011.041251","article-title":"Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib","volume":"96","author":"Breccia","year":"2011","journal-title":"Haematologica"},{"issue":"25","key":"10.1016\/j.jgo.2018.01.008_bb0300","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Quintas-Cardama","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2018.01.008_bb0305","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","article-title":"Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis","volume":"141","author":"de Lavallade","year":"2008","journal-title":"Br J Haematol"},{"issue":"17","key":"10.1016\/j.jgo.2018.01.008_bb0310","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jgo.2018.01.008_bb0315","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.leukres.2008.09.026","article-title":"Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia","volume":"33","author":"Rasheed","year":"2009","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.jgo.2018.01.008_bb0320","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","article-title":"Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia","volume":"32","author":"Dusetzina","year":"2014","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.jgo.2018.01.008_bb0325","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2018.01.008_bb0330","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1200\/JOP.2016.014639","article-title":"Financial burden for patients with chronic myeloid leukemia enrolled in Medicare part D taking targeted oral anticancer medications","volume":"13","author":"Shen","year":"2017","journal-title":"J Oncol Pract"},{"issue":"4 Suppl","key":"10.1016\/j.jgo.2018.01.008_bb0335","first-page":"s78","article-title":"High cost sharing and specialty drug initiation under Medicare part D: a case study in patients with newly diagnosed chronic myeloid leukemia","volume":"22","author":"Doshi","year":"2016","journal-title":"Am J Manag Care"},{"issue":"36","key":"10.1016\/j.jgo.2018.01.008_bb0340","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1200\/JCO.2016.67.4184","article-title":"Factors associated with tyrosine kinase inhibitor initiation and adherence among medicare beneficiaries with chronic myeloid leukemia","volume":"34","author":"Winn","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2018.01.008_bb0345","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1182\/blood.V128.22.630.630","article-title":"Generic imatinib in chronic myeloid leukemia: survival of the cheapest [abstract]","volume":"128","author":"Madhav","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2018.01.008_bb0350","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood.V128.22.629.629","article-title":"Imatinib generics in treatment of chronic myeloid leukemia; a prospective observation in large cohort of patients from Polish (PALG) imatinib generics registry [abstract]","volume":"128","author":"Sacha","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2018.01.008_bb0355","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1182\/blood.V128.22.1899.1899","article-title":"Outcome of frontline treatment with generic imatinib in adult patients with chronic myeloid leukemia in Algerian population: a first multicenter study [abstract]","volume":"128","author":"Entasoltan","year":"2016","journal-title":"Blood"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406818300262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406818300262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T08:01:18Z","timestamp":1603872078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406818300262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S1879406818300262"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2018.01.008","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to treat chronic myeloid leukemia (CML) in older adults","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2018.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}